Skip to main content
TipRanks
Go Ultimate75% OFF

Tryptamine Therapeutics (ENP) Ownership - Who Owns Tryptamine Therapeutics?

19 Followers

Tryptamine Therapeutics (ENP) Ownership Overview

  • 11.50% Insiders
  • 88.50% Public Companies and Individual Investors

The ownership structure of Tryptamine Therapeutics (AU:ENP) stock is a mix of institutional, retail, and individual investors. , 11.50% is owned by Insiders, and 88.50% is owned by Public Companies and Individual Investors.

Recent Insider Trading Activity

Recent Insider Trading Activity
DateNameActivityValue
May 13, 2026Jason Alan CarrollAU$45,604
Apr 19, 2026Chris NtoumenopoulosAU$100,000
Apr 19, 2026Daniel TillettAU$170,000
Apr 19, 2026Jason Alan CarrollAU$150,000

Recent Hedge Fund Trading Activity

Recent Hedge Fund Trading Activity
DateFirmActivityValue

Top Shareholders

AU:ENP top shareholders
Holder# of SharesType% HoldingValue
Daniel Tillett67,000,000Insider4.10%1,206,000
Jason Alan Carroll62,500,000Insider3.82%1,125,000
Herwig Janssen39,304,107Insider2.41%707,474
Chris Ntoumenopoulos19,191,176Insider1.17%345,441

FAQ

What percentage of Tryptamine Therapeutics (AU:ENP) stock is held by retail investors?
According to the latest TipRanks data, approximately 88.50% of Tryptamine Therapeutics (AU:ENP) stock is held by public companies and individual investors.
Who owns the most shares of Tryptamine Therapeutics (AU:ENP)?
Daniel Tillett owns the most shares of Tryptamine Therapeutics (AU:ENP).
What is the significance of the ownership structure for a publicly traded company?
The ownership structure can impact the company's decision making, as large institutional investors may exert influence on the company's management and can also affect the company's stock price with their buying and selling patterns.